Quantitative measurement of human papillomavirus type 16 E5 oncoprotein levels in epithelial cell Lines by mass spectrometry

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9465-9473

  Sahab, Ziad ^b   Sudarshan, Sawali R ^a   Liu, Xuefeng ^a   Zhang, YiYu ^a   Kirilyuk, Alexander ^b   Kamonjoh, Christopher M ^a   Simic, Vera ^a   Dai, Yuhai ^a   Byers, Stephen W ^b   Doorbar, John ^c   Suprynowicz, Frank A ^a   Schlegel, Richard ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL PHENYALANYLLEUCYLISOLEUCYLTHREONINE; HUMAN PAPILLOMAVIRUS TYPE 16 E5 ONCOPROTEIN; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; TETRAPEPTIDE; TRYPSIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA TRANSCRIPTION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; UTERINE CERVIX CANCER;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MASS SPECTROMETRY; MICE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PEPTIDE MAPPING; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS MUSCULUS;

EID: 84866144195     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01032-12     Document Type: Article

References (64)

1. Allen-Hoffmann BL, et al. 2000. Norman growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Invest. Dermatol. 114: 444-455.
2. Arbeit JM, Munger K, Howley PM, Hanahan D. 1994. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68: 4358-4368.
3. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS. 2006. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 119: 2105-2112.
4. Baege AC, Berger A, Schlegel R, Veldman T, Schlegel R. 2002. Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity. Am. J. Pathol. 160: 1251-1257.
5. Baker CC, et al. 1987. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61: 962-971.
6. Bauer-Hofmann R, et al. 1996. Genomic cloning and characterization of the nonoccupied allele corresponding to the integration site of human papillomavirus type 16 DNA in the cervical cancer cell line SiHa. Virology 217: 33-41.
7. Bouvard V, Matlashewski G, Gu ZM, Storey A, Banks L. 1994. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 203: 73-80.
8. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56: 4620-4624.
9. Chang JL, et al. 2001. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J. Biomed. Sci. 8: 206-213.
10. Chapman S, Liu X, Meyers C, Schlegel R, McBride AA. 2010. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J. Clin. Invest. 120: 2619-2626.
11. Choo KB, et al. 1987. Presence of episomal and integrated human papillomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 21: 101-107.
12. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88: 63-73.
13. Collins SI, et al. 2009. Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Res. 69: 3828-3832.
14. Corden SA, Sant-Cassia LJ, Easton AJ, Morris AG. 1999. The integration of HPV-18 DNA in cervical carcinoma. Mol. Pathol. 52: 275-282.
15. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A. 1998. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 241: 76-83.
16. Cullen AP, Reid R, Campion M, Lorincz AT. 1991. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65: 606-612.
17. Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R. 2003. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 311: 105-114.
18. Fehrmann F, Laimins LA. 2003. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22: 5201-5207.
19. Forsman A, Ruetschi U, Ekholm J, Rymo L. 2008. Identification of intracellular proteins associated with the EBV-encoded nuclear antigen 5 using an efficient TAP procedure and FT-ICR mass spectrometry. J. Proteome Res. 7: 2309-2319.
20. Genther Williams SM, et al. 2005. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65: 6534-6542.
21. Gruener M, Bravo IG, Momburg F, Alonso A, Tomakidi P. 2007. The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol. J. 4: 116
22. Hafner N, et al. 2008. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27: 1610-1617.
23. Huh KW, et al. 2005. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Natl. Acad. Sci. U. S. A. 102: 11492-11497.
24. Isaacson Wechsler E, et al. 2012. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J. Virol. 86: 6358-6364.
25. Jeon S, Allen-Hoffmann BL, Lambert PF. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69: 2989-2997.
26. Kabsch K, et al. 2004. The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte raft cultures. Intervirology 47: 48-56.
27. Kell B, et al. 1994. Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. J. Gen. Virol. 75: 2451-2456.
28. Krawczyk E, Hanover JA, Schlegel R, Suprynowicz FA. 2008. Karyopherin beta3: a new cellular target for the HPV-16 E5 oncoprotein. Biochem. Biophys. Res. Commun. 371: 684-688.
29. Krawczyk E, et al. 2008. Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins. Am. J. Pathol. 173: 682-688.
30. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
31. Lemaire R, et al. 2007. Direct analysis and MALDI imaging of formalinfixed, paraffin-embedded tissue sections. Proteome Res. 6: 1295-1305.
32. Lewis JK, Bendahmane M, Smith TJ, Beachy RN, Siuzdak G. 1998. Identification of viral mutants by mass spectrometry. Proc. Natl. Acad. Sci. U. S. A. 95: 8596-8601.
33. Li M, Garcea RL. 1994. Identification of the threonine phosphorylation sites on the polyomavirus major capsid protein VP1: relationship to the activity of middle T antigen. J. Virol. 68: 320-327.
34. Lim PS, et al. 1990. Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides. J. Infect. Dis. 162: 1263-1269.
35. Liu X, et al. 2012. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180: 599-607.
36. Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. 2008. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 375: 611-623.
37. Matsukura T, Koi S, Sugase K. 1989. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 172: 63-72.
38. Mincheva A, Gissmann L, zur Hausen H. 1987. Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization. Med. Microbiol. Immunol. 176: 245-256.
39. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587-3596.
40. Munger K, et al. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8: 4099-4105.
41. Pater MM, Pater A. 1985. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 145: 313-318.
42. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U. S. A. 90: 8392-8396.
43. Pim D, Collins M, Banks L. 1992. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 7: 27-32.
44. Pirami L, Giache V, Becciolini A. 1997. Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50: 600-604.
45. Regan JA, Laimins LA. 2008. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 82: 10042-10051.
46. Riley RR, et al. 2003. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63: 4862-4871.
47. Rodriguez J, Gupta N, Smith RD, Pevzner PA. 2008. Does trypsin cut before proline? J. Proteome Res. 7: 300-305.
48. Romanczuk H, Howley PM. 1992. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl. Acad. Sci. U. S. A. 89: 3159-3163.
49. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
50. Sherman L, Alloul N, Golan I, Durst M, Baram A. 1992. Expression and splicing patterns of human papillomavirus type-16 mRNAs in precancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers. Int. J. Cancer 50: 356-364.
51. Shirasawa H, et al. 1988. Transcriptional differences of the human papillomavirus type 16 genome between precancerous lesions and invasive carcinomas. J. Virol. 62: 1022-1027.
52. Shirasawa H, Tomita Y, Sekiya S, Takamizawa H, Simizu B. 1987. Integration and transcription of human papillomavirus type 16 and 18 sequences in cell lines derived from cervical carcinomas. J. Gen. Virol. 68: 583-591.
53. Stoppler MC, Straight SW, Tsao G, Schlegel R, McCance DJ. 1996. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 223: 251-254.
54. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. 1993. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67: 4521-4532.
55. Suprynowicz FA, Campo MS, Schlegel R. 2006. Biological activitites of papillomavirus E5 proteins, p 97-113. In Campo MS (ed), Papillomavirus research: from natural history to vaccines and beyond. Caister Academic Press, Wymondham, United Kingdom.
56. Suprynowicz FA, Disbrow GL, Simic V, Schlegel R. 2005. Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16? Virology 332: 102-113.
57. Suprynowicz FA, et al. 2010. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J. Virol. 84: 10619-10629.
58. Thomsen P, van Deurs B, Norrild B, Kayser L. 2000. The HPV-16 E5 oncogene inhibits endocytic trafficking. Oncogene 19: 6023-6032.
59. Thorland EC, Myers SL, Gostout BS, Smith DI. 2003. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22: 1225-1237.
60. Valle GF, Banks L. 1995. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J. Gen. Virol. 76: 1239-1245.
61. Veldman T, Horikawa I, Barrett JC, Schlegel R. 2001. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 75: 4467-4472.
62. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79.
63. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM. 1985. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119: 361-366.
64. zur Hausen H, de Villiers EM. 1994. Human papillomaviruses. Annu. Rev. Microbiol. 48: 427-447.